Epstein-Barr Viral Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Epstein-Barr Viral Infections - Pipeline Review, H2 2016

Epstein-Barr Viral Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Epstein-Barr Viral Infections - Pipeline Review, H2 2016
Published Aug 10, 2016
71 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Epstein-Barr Viral Infections - Pipeline Review, H2 2016, provides an overview of the Epstein-Barr Viral Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epstein-Barr Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epstein-Barr Viral Infections and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections
- The report reviews pipeline therapeutics for Epstein-Barr Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Epstein-Barr Viral Infections therapeutics and enlists all their major and minor projects
- The report assesses Epstein-Barr Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Epstein-Barr Viral Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devis

  
Source:
Document ID
GMDHC8337IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Epstein-Barr Viral Infections Overview91
Therapeutics Development102
  Pipeline Products for Epstein-Barr Viral Infections Overview101
  Pipeline Products for Epstein-Barr Viral Infections Comparative Analysis111
Epstein-Barr Viral Infections Therapeutics under Development by Companies121
Epstein-Barr Viral Infections Therapeutics under Investigation by Universities/Institutes131
Epstein-Barr Viral Infections Pipeline Products Glance143
  Late Stage Products141
  Clinical Stage Products151
  Early Stage Products161
Epstein-Barr Viral Infections Products under Development by Companies171
Epstein-Barr Viral Infections Products under Investigation by Universities/Institutes181
Epstein-Barr Viral Infections Companies Involved in Therapeutics Development1911
  Arno Therapeutics, Inc.191
  Cell Medica Limited201
  Epiphany Biosciences, Inc.211
  Genocea Biosciences, Inc.221
  Humabs BioMed SA231
  Molplex Ltd.241
  Omeros Corporation251
  Savoy Pharmaceuticals, Inc.261
  Theravectys SA271
  Vironika, LLC281
  ViroStatics srl291
Epstein-Barr Viral Infections Therapeutics Assessment309
  Assessment by Monotherapy Products301
  Assessment by Target312
  Assessment by Mechanism of Action332
  Assessment by Route of Administration352
  Assessment by Molecule Type372
Drug Profiles3929
  AR-12 Drug Profile393
  Cellular Immunotherapy for EBV Associated PTLD Drug Profile421
  Cellular Immunotherapy for Infectious Disease Drug Profile431
  Cellular Immunotherapy for Infectious Diseases Drug Profile441
  Cellular Immunotherapy for Systemic Lupus Erythematosus and Epstein-Barr Viral Infections Drug Profile451
  Cellular Immunotherapy for Viral Infections Drug Profile461
  Cellular Immunotherapy for Viral Infections Post-HSCT Drug Profile471
  Cellular Immunotherapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma Drug Profile481
  Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection Drug Profile491
  Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases Drug Profile501
  Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile511
  CMD-003 Drug Profile522
  Epstein-Barr virus (virus like particle) vaccine Drug Profile541
  Epstein-Barr virus vaccine Drug Profile551
  Monoclonal Antibody for Epstein-Barr Viral Infection Drug Profile561
  MVA vaccine Drug Profile571
  Small Molecule for Infectious Mononucleosis Drug Profile581
  Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections Drug Profile591
  Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections Drug Profile602
  Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections Drug Profile621
  Small Molecules to Inhibit EBNA1 for Epstein-Barr Viral Infections Drug Profile631
  Vaccine for Epstein-Barr Virus and Oncology Drug Profile641
  valomaciclovir stearate Drug Profile652
  Viroprev Drug Profile671
Epstein-Barr Viral Infections Dormant Projects681
Epstein-Barr Viral Infections Product Development Milestones691
  Featured News &Press Releases691
    Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus691
Appendix702
  Methodology701
  Coverage701
  Secondary Research701
  Primary Research701
  Expert Panel Validation701
  Contact Us701
  Disclaimer711

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Epstein-Barr Viral Infections - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Epstein-Barr-Viral-Infections-Pipeline-Review-H2-2016-2088-16345>
  
APA:
Global Markets Direct - Market Research. (2016). Epstein-Barr Viral Infections - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Epstein-Barr-Viral-Infections-Pipeline-Review-H2-2016-2088-16345>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.